SLC5A2 and prostate carcinoma: In order to investigate the causal link between SGLT2 inhibitors and prostate cancer risk via circulating metabolites or metabolite ratios, we conducted a two-sample, two-step MR study to delve into the hypothetical metabolic pathways that might interconnect the pharmacological action of SGLT2 inhibitors with the development of prostate cancer.